BioNTech shares closed Friday at EUR 78.05, down 3.0% on the session, capping a bruising stretch for the Mainz-based vaccine and oncology developer. Over the past seven days the stock has shed 9.8% of its value, and it now sits 26% below its 52-week high.
The retreat has been driven by two distinct forces pulling in the same direction. The first is a broad selloff in the US technology sector that weighed on equities generally, according to the news agency AP. The second is a clinical disappointment that has been gnawing at investor confidence since Tuesday, when the company disclosed an update on an advanced cancer study.
A Dual Endpoint, Only Half Answered
At the heart of the setback is BNT113, an mRNA-based cancer immunotherapy that BioNTech is testing in combination with pembrolizumab in the Phase 2/3 AHEAD-MERIT trial. The candidate targets patients with metastatic, HPV16-positive head and neck cancer.
An interim analysis delivered unwelcome news: the combination failed to reach the first of two dual primary endpoints — progression-free survival. The trial did not demonstrate statistical significance for the combination over pembrolizumab monotherapy on that measure. German business daily Handelsblatt characterised the outcome as a blow for the company.
Yet the study is not over. BioNTech confirmed that AHEAD-MERIT will continue, because the second dual primary endpoint — overall survival — has yet to be assessed. The company also filed a Form 6-K report with the US Securities and Exchange Commission to meet its capital-market disclosure obligations.
Should investors sell immediately? Or is it worth buying BioNTech?
Canaccord Trims Its Target, Keeps Its Conviction
Analysts moved quickly to recalibrate. Canaccord Genuity cut its price target on BioNTech on Wednesday from $136 to $132, an adjustment the firm attributed to an update of its valuation model following the release of the progression-free survival data. Despite the lower target, the analysts reiterated their “Buy” rating on the stock.
The week also brought a separate disclosure: a mandatory filing covering a transaction by chief executive Ugur Sahin, who sold shares under a pre-arranged trading plan adopted under US Rule 10b5-1. Such programmes are designed to execute insider sales on fixed parameters, independent of day-to-day market movements.
What Hangs in the Balance
For investors, the oncology pipeline remains the decisive factor in judging BioNTech’s longer-term prospects. Whether BNT113 can still deliver partially on expectations in the HPV16-positive head and neck cancer indication now rests on forthcoming analyses of overall survival. Until those readouts arrive, the stock’s recovery — and the credibility of its cancer franchise — will be measured against that single remaining endpoint.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from October 17 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 17.
BioNTech: Buy or sell? Read more here...
